key: cord-1027029-fqbpx3pp
authors: Swenson, Kai E.; Swenson, Erik R.
title: Pathophysiology of ARDS and COVID-19 Lung Injury
date: 2021-05-28
journal: Crit Care Clin
DOI: 10.1016/j.ccc.2021.05.003
sha: a260181ff860ce944ae16af6fc6a55f39d7551a4
doc_id: 1027029
cord_uid: fqbpx3pp

Acute respiratory distress syndrome (ARDS) is a rapidly developing non-cardiogenic pulmonary edema caused by pulmonary and systemic infections or sterile tissue injuries that evoke a severe lung-damaging host inflammatory response. The lung loses its normal gas exchange efficiency with disruption of the tight permeability characteristics of the alveolar capillary barrier. Interstitial and subsequent alveolar edema lead to alveolar collapse/de-recruitment, reduced lung compliance and greater pulmonary vascular resistance, often with marked regional heterogeneity in severity. Regional heightened stress applied to surrounding normal or less injured lung from edematous and collapsed regions along with associated barotrauma, volutrauma and atelectrauma with mechanical or extreme spontaneous ventilatory efforts further propagate injury in a vicious cycle called ventilator induced lung injury. Resulting arterial hypoxemia and hypercapnia arise from the creation of regions of shunt and low ventilation-perfusion (V(A)/Q) ratios, in addition to creation of high V(A)/Q and dead space areas by blood flow obstruction with thrombosis and/or high ventilating pressures. The pathophysiology of ARDS is discussed in this article and focuses on changes in the lung parenchyma and vasculature that reduce compliance, increase vascular resistance and compromise maintenance of dry normally compliant alveolar space by active alveolar fluid clearance and passive lymphatic fluid clearance from the lung interstitium. The COVID-19 pandemic that has emerged with the novel coronavirus, SARS-CoV-2, has generated a new form of severe acute lung injury that resembles ARDS in many of its features, but has different characteristics in its earliest stages leading to more profound hypoxemia and loss of dyspnea perception with less radiologically evident lung injury, not described before in ARDS. Understanding the pathophysiological features of ARDS and COVID-19 lung injury is critical to the best use of supportive therapies such as low tidal volume ventilation, supplemental oxygen concentrations, positive end-expiratory pressure (PEEP), permissive hypercapnia, prone positioning and neuromuscular blockade.

ARDS is a complex syndrome of acute lung injury leading to non-cardiogenic pulmonary edema from many causes that is heterogenous in its clinical presentation and associated with a 40% mortality rate. [1] Extensive work since its initial description in 1967 has elucidated biological pathways causing the many physiologic changes of alveolar collapse/de-recruitment, reduced lung compliance, greater pulmonary vascular resistance, and gas exchange impairment which can be compounded by patient's own ventilatory response or assisted ventilatory support, due to regional heterogeneity of the underlying lung injury.

It is useful to briefly review the pathogenesis of lung injury and repair in ARDS to understand its effects on physiology. Injury begins with activation of alveolar macrophages by microbial or cell injury products, [2] which are locally derived in primary lung injury (pulmonary ARDS) or systemically derived (extrapulmonary ARDS). Cytokine/chemokine release by macrophages recruits and activates circulating neutrophils, which release myriad inflammatory molecules. Although assisting with pathogen killing, they also injure the normally tight alveolar endothelial-epithelial barrier consisting of adherent cell-cell contacts and glycocalyx linings. [3] Alveolar type II pneumocytes secrete surfactant and along with type I pneumocytes reabsorb alveolar fluid by active ion transport back into the interstitium for lymphatic clearance. [4] As a result of loss of the normal low permeability characteristics, the alveolar space fills with an inflammatory cell-rich proteinaceous edema fluid (exudative phase of ARDS), a prime determinant of lung injury severity, alveolar collapse and de-recruitment. [5] In the proliferative phase of ARDS with clearance of pathogens and damaged host cells from the alveolar space, the immune response is recalibrated to prioritize repair and restoration of normal function. This involves neutrophil apoptosis and removal, expansion of resident fibroblasts and interstitial matrix reformation, and regrowth of alveolar epithelium by differentiation of Type II alveolar cells into Type I cells. If the proliferative phase is impaired or prolonged, ongoing inflammation and fibroblast proliferation impair alveolar clearance and functional recovery. [6] It is likely that uncleared, insoluble proteins in the alveolar space (forming hyaline membranes observed histologically), seed the formation of fibrotic tissue by mesenchymal cells, ultimately leading to the long term consequence of fibrosing alveolitis (fibrotic phase of ARDS) in some but not all patients.

The consequences of the above changes to alveolar structure and histology are gas exchange impairment, increased work of breathing and dyspnea leading to respiratory failure. Alveolar flooding along with pulmonary vascular injury generates the entire spectrum of V A /Q abnormalities from areas with reduced ventilation-to-perfusion (V A /Q) ratios, intrapulmonary shunting, to high V A /Q ratios and dead space ( Figure 1 ). Low V A /Q and shunt are responsible for increased venous admixture and arterial hypoxemia. Given little or no ventilation to these areas, arterial hypoxemia is insensitive to global increases in ventilation. Increased F I O 2 can improve oxygenation in low V A /Q regions, though not in shunts. Although alveolar and interstitial edema widens the alveolar-capillary barrier, the impact of diffusion limitation in causing hypoxemia is dwarfed by contributions of low V A /Q and shunt [7] as demonstrated by the multiple inert gas elimination technique (MIGET). Increases in alveolar oxygen with higher F I O 2 minimize the impact of any diffusion limitation by increasing the alveolar-capillary oxygen driving gradient. Finally, intra-cardiac shunting can develop in patients with a pre-existing patent foramen ovale (PFO), who develop elevated right heart pressures because of increased pulmonary vascular resistance (PVR).

Hypercapnia can also occur but is not incorporated into any ARDS definitions. Several aspects of CO 2 elimination in ARDS merit discussion. As is the case for oxygen uptake, V A /Q mismatching also impairs CO 2 elimination. Although a diffusion impairment for CO 2 does not occur due to its very high solubility in blood and tissue water and a 20-fold greater diffusivity over oxygen, any failure of alveolar-capillary CO 2 equilibration (widened a-A PCO 2 gradient) results from rapid capillary transit times and several relatively slower steps in blood CO 2 chemistry including red cell membrane chloride-bicarbonate exchange and the Bohr-Haldane effects. [8] Both high and low V A /Q regions (including shunt) contribute significantly to hypercapnia, as clarified using MIGET [9] since mixed venous blood flowing through low V A /Q units enters into the systemic arterial circulation with little or no CO 2 elimination. [10] The use of the Bohr-Enghoff equation to estimate dead space with values as high as 75% [11] overestimates the magnitude of physiologic dead space in ARDS occurring from vascular obstruction and vasoconstriction [9] . Nonetheless, a rising CO 2 dead space may be associated with increased vascular resistance and right heart dysfunction indicative of vascular obstruction. [12] Increases in minute ventilation can effectively improve CO 2 elimination from less injured regions due to the steepness of the blood CO 2 dissociation curve and even cause arterial hypocapnia; but become less effective as V A /Q mismatching worsens and increased work of breathing generates more CO 2. Ventilation of high V A /Q regions, especially dead space (V A /Q > 100), wastes respiratory effort without contributing to CO 2 elimination. [13] Hypercapnia with protective lung ventilation is better accepted since the landmark ARDSnet study showing mortality reduction with this strategy. [14] However, whether this permissive hypercapnia itself might have benefits remains uncertain. It may have both positive and deleterious effects on the ongoing process of lung injury, such as attenuation of lung inflammation, but reduction in alveolar fluid clearance. [15, 16] Regional differences in lung density, ventilation, and blood flow in ARDS ARDS does not affect the lung uniformly as shown by CT imaging (Figure 2 ). The greatest degree of edema, parenchymal densities, consolidation and shunting are often in the dorsal and basilar regions of the lung particularly in the supine position, the position in which most patients are maintained while on mechanical ventilation and/or during hemodynamic instability. However, this heterogeneity can be altered with position changes such as with turning to the prone position. [17] Quantification of heterogeneity in lung units using MIGET demonstrates indirectly a wide range of V A /Q lung units, with a bimodal distribution of considerable shunt and elevated alveolar dead space, [18] but it provides no regional information. Advanced imaging techniques, including radio-labelled inert gas inhalation/infusion, can provide spatial resolution for the physiologic heterogeneity seen with MIGET in ARDS. [19] Areas of lowest ventilation and lowest V A /Q (areas of CT densities) are found in gravitationally dependent regions; regional ventilation heterogeneity is greater in the supine than in the prone position (Figure 3) , likely a consequence of the more compressive effect of lung and soft tissue weight (cardiac and abdominal) on basilar lung regions and higher regional pleural pressure differences in the supine position. [20] Oxygenation in ARDS improves in most patients with prone positioning resulting from the reduction in regional V A /Q heterogeneity.

Pulmonary blood flow, on the other hand, is less affected by gravitational forces and positioning, [21] as regional blood vessel density and local vascular tone are the primary determinants of regional perfusion. Perfusion is higher in posterior and caudal lung regions, and therefore prone positioning (which improves ventilation in these areas) is associated with significant gas exchange improvement in most patients with ARDS. Pulmonary vascular tone is presumed to be mediated most directly by hypoxic pulmonary vasoconstriction (HPV) and hypercapnic pulmonary vasoconstriction that redirect perfusion to greater ventilated and oxygenated lung units to optimize V A /Q matching. The only direct evidence that HPV is operative and contributes significantly to regional vascular tone in ARDS, since it has never been tested formally by hypoxic gas inspiration, [22] comes from patients receiving extracorporeal membrane oxygenation in whom mean PA pressure decreased and PVR fell 25% when the mixed venous PO 2 was raised from 47 to 84 mmHg by increasing extracorporeal blood flow. [23] HPV augmentation with pulmonary vasoconstrictors (almitrine) and inhalation of pulmonary vasodilators (such as nitric oxide) to vasodilate ventilated areas are both associated with reductions in hypoxemia; the latter treatment, however, only exerts effects on ventilated lung units to which it can be delivered. [24] Respiratory mechanics in ARDS J o u r n a l P r e -p r o o f Lung parenchyma is formed from millions of interdependent alveoli, which share the alveolar volume throughout the lung, preventing overdistension during inspiration and collapse during expiration. [25] This allows for parenchymal stress during inspiration to be somewhat homogenized, despite variability in alveolar size and location. In ARDS, increased permeability, as well as loss of surfactant, cause some alveoli to become flooded and unrecruitable or poorly recruitable. As a result, lung volume remaining for gas exchange shrinks, and lung compliance is reduced, though it varies widely based on disease severity from 5 to 40 ml/cmH 2 0 [26, 27] and functional residual capacity is decreased by 20-30% compared to normal. [28] The volume of de-recruited lung appears to roughly correlate with the degree of pulmonary shunt and gas exchange abnormalities. [29] It has been long recognized that alveolar edema and de-recruitment occur in a heterogeneous regional fashion with dependent regions most affected. [30, 31] Focal and nonfocal patterns of lung involvement in ARDS respond differently to recruitment maneuvers such as PEEP or position change. [32] These radiographic findings reinforce the idea that the lung in ARDS can be conceptually divided into non-aerated diseased regions and aerated healthy regions. The diminished size of normal aerated lung tissue in relation to overall lung mass has been termed the "baby lung in an adult body". [26] As is clear from the radiographic studies above, the "baby lung" need not be a distinct anatomic but rather a physiologic entity, and its area can shift dramatically depending on body position. [30] Global measurements of compliance, and airway, plateau and transpulmonary pressures may not adequately account for such regional variation in physiology. For example, there may be significant variations in pleural pressure in ARDS, especially between dependent and nondependent regions, which are not captured by a point estimate of pleural pressure via esophageal balloon and can be as high as 10 cmH 2 0 in cadaveric studies. [33] Additionally, airway pressure measurements may not accurately estimate local stresses in regions with airway closure, particularly in obese patients. [34] These regional variations in compliance can lead to a heterogeneous injury risk. In a process called stress concentration, local alveolar de-recruitment causes inhomogeneity in distending pressures, with surrounding alveoli bearing the greatest stress. In effect, this creates a penumbra of at-risk lung units ( Figure 4 ) surrounding an area of injury, which may propagate. [35, 36] These areas have been termed "stress raisers" and may involve up to a quarter of the parenchyma as visualized by dynamic CT imaging. Mechano-transduction associated with shear stresses caused by cyclic atelectasis in these regions may contribute to cleavage of cell-cell adhesion molecules, further disrupting membranes and preventing alveolar clearance of edema. [37] Despite retaining grossly normal mechanical properties, [38] PET imaging demonstrates that well-aerated lung regions have abnormal permeability and higher metabolic rate, suggesting ongoing and worsening inflammation even with lung protective ventilation. [39, 40] Though ARDS is predominantly a restrictive disorder, airway obstruction can also occur from edematous distal airways and increased lung weight causing small airway narrowing/closure, with total airway resistance elevated roughly two-fold. [41] Expiratory flow limitation does appear to exist in ARDS and improves with PEEP though not with bronchodilators. [42] Although rapid flows and rapid changes in pressure likely exert some degree of additional stress to the lung parenchyma given its viscoelastic nature, the clinical importance of this stress is not fully known.

The ability of the lung to maintain a highly compliant and dry alveolar air space for efficient gas exchange at a low work of breathing cost depends upon a number of factors, including surfactant production and active vectorial alveolar epithelial sodium and water transport from the alveolar space into the interstitium for re-uptake into the blood or lymphatic transport. In ARDS, surfactant is inactivated, and alveolar epithelial injury leads to loss of fluid reabsorption ( Figure 5 ). Type I and II alveolar epithelial cells actively reabsorb sodium and fluid from the airspace via apical membrane sodium entry through epithelial sodium channels (ENaC) driven by the concentration gradient established by sodium pumping into the interstitium by basolateral membrane energy-consuming Na + /K + ATPase. [43] Chloride follows paracellularly and via CFTR-mediated transcellular uptake [44] and water by paracellular movement and by aquaporin-5 mediated transcellular movement. [45] Fluid reabsorption rates in the isolated human lung average about 12 % per hour [46] but likely are higher in vivo. Reabsorption can be stimulated several-fold by beta-2 adrenergic agonist-and corticosteroid-mediated upregulation of ENaC and Na + /K + ATPase membrane expression and activity. [43, 46] Fluid clearance from the lung interstitium by lung lymphatics is mediated passively by ventilatory efforts and by active spontaneous contractions, which can be stimulated by beta-2 adrenergic drugs [47] that may enhance lymph drainage out of the lung.

In conditions in which the alveolar epithelium is not injured, such as cardiogenic pulmonary edema, beta-2 adrenergic agonists increase fluid reabsorption, but the hope that this might be realized in ARDS could not be demonstrated in two large clinical trials involving systemic [48] and inhaled [49] drug administration. The success in heart failure and lack of efficacy in ARDS is likely explained by a functioning intact alveolar epithelium in cardiogenic pulmonary edema and injury and denudation of the epithelium in acute lung injury, either unable to reabsorb sodium at all or keep pace with ongoing rates of microvascular leakage. The increase in alveolar surface tension with cessation of production and inactivation of surfactant in ARDS leads to a lower interstitial pressure which increases the microvascular transmural pressure gradient. This favors greater extravascular fluid accumulation for the same microvascular pressure. [50] 

An understanding of ARDS physiology, whose key features include gas exchange abnormalities often requiring ventilatory support and atelectasis/decreased compliance with significant regional heterogeneity, has implications f1or the ventilatory support strategies. The role of lung injury while on positive pressure ventilation is the best studied. Positive pressure ventilation along with positive end expiratory pressure (PEEP) reduce work of breathing and prevent atelectasis of nearly-collapsed lung units to improve gas exchange. Furthermore, positive airway pressure helps to reduce further edema formation in many edematous states, including the increased alveolar permeability of ARDS. [51] However, as long known, mechanical ventilation also exacerbates the ongoing processes of lung injury and even injury to other critical organs beyond the lung ( Figure 6 ), broadly termed ventilator-induced lung injury (VILI). VILI is often differentiated at the extremes of lung volume; [52] injury at high lung volumes is due to alveolar overdistension (barotrauma/volutrauma), whereas injury at low lung volumes is due to cyclical opening and closing of distal airways and alveoli (atelectrauma). High respiratory rate and inspiratory flow theoretically would increase total stress at both high and low lung volumes, although the effect of these variables within normal clinical ranges on progression of injury remains uncertain. [53] Other etiologies of VILI include patient selfinflicted lung injury (P-SILI) described below, and biotrauma, the downstream local and systemic biological effects of all ventilation-related injury.

Volutrauma and barotrauma represent two depictions of the same process, in which excessive mechanical power causes alveolar overdistension and repetitive strain [54] and has been well-described for decades. [55] Clinical strategies to avoid volutrauma and barotrauma, termed lung-protective ventilation, are strongly associated with improved mortality in ARDS. [14] These include targeted tidal volumes of 6 ml/kg ideal body weight, plateau pressures < 30 cmH 2 0, driving pressures (plateau pressure -PEEP) < 16 cmH 2 O, and judicious PEEP; however, even these goals may not be adequately protective. None allow for delivered tidal volumes to scale with the fraction of non-aerated lung; a more individualized approach would incorporate some measurement of aerated lung volume, such as with nitrogen wash-in/washout or helium dilution techniques, or CT quantitation of aerated lung volume. [56] It is important to note that plateau pressure decreases as the duration of time spent at end-inspiratory occlusion lengthens, likely due to delayed recruitment of additional lung volume via surfactant spread and alveolar pendelluft. Thus, a shorter end-inspiratory occlusion plateau pressure is recommended as a marker of lung injury. [27] Additionally, plateau pressures may not correlate well with transpulmonary pressure, especially if there is significant extrathoracic restriction, such as with severe obesity, ascites, advanced pregnancy or extensive thoracic burns. [57] Lastly, regional heterogeneity of lung compliance can lead to local overdistension, as visualized on CT, despite global lung protective ventilation; [58] this likely occurs predominantly in areas of stress concentration. Various bedside techniques, especially electrical impedance tomography (EIT) to non-invasively monitor changes in regional lung ventilation across the transverse plane of the chest, may help tailor ventilatory support to avoid such injury. [59] Gross overdistension and rupture of alveoli can also lead to pneumothorax, pneumomediastinum and air embolism in ARDS, though this is rare in the age of lung protective ventilation.

Injury at low lung volumes due to stresses from cyclical opening and closing of alveoli and distal airways, associated with parenchymal shear injury, is collectively termed alelectrauma. Animal models of ARDS demonstrate that cyclical opening and closing of alveolar ducts and even bronchioles (depending on level of PEEP) leads to site-specific lung injury, [60] which correlates with findings in human lungs on autopsy series. [61] Pressures required to maintain open airways vary depending on patient and lung region, but globally can be as high as 13 cmH 2 0 when monitoring the lower inflection point of the pressure/volume curve. [62] Thus, injury from cyclical atelectasis may be prevented with application of higher PEEP. [63] Although large trials of high vs low PEEP in ARDS have shown no mortality reduction, [64, 65] there are likely patient subsets who might benefit from higher or lower PEEP. Notably, decremental PEEP trials to identify the pressure-volume curve associated with the best dynamic compliance ("open lung strategy") may reduce mortality in ARDS. [66, 67] PEEP titration targeting a transpulmonary pressure of 0-10 cmH 2 O at end expiration using esophageal balloon pressure measurement for estimation of pleural pressure is also promising for optimizing respiratory parameters and reducing overall lung injury.

[68] Evaluation of regional recruitability continues to be an active area of investigation; emerging bedside techniques include the multiple pressure-volume curves method [69] and EIT. [59] The genetic, molecular and cell biological events of parenchymal stress and strain in all types of VILI is termed biotrauma. It is the cellular response to alveolar and small airway cellular injury with gene transcription and elaboration of numerous pro-inflammatory mediators that drive ongoing lung injury and cause systemic organ damage and dysfunction. [70] These processes, mediators and their effects are more fully presented by other articles in this series.

Afferent signaling to the CNS of impaired gas exchange, lung irritant and stretch receptor activation, and work of breathing can lead to vigorous injurious respiratory efforts to both diseased and at-risk lung regions even when tidal volumes and plateau pressures are limited. [71] Convincing data come from animal models, in which neurologically-stimulated hyperventilation itself directly induces acute lung injury. [72] It is likely that the effects of P-SILI are most profound on basilar lung units where swings in local intrapleural negative pressure caused by the proximity of the diaphragm are greatest. [73] [74] [75] Most clinical data suggesting P-SILI derive from studies correlating spontaneous breathing efforts during mechanical ventilation with increased mortality. Despite similar tidal volumes and plateau pressures, assisted breaths can lead to worsened lung injury in early ARDS as compared to controlled breaths, offering supportive evidence for neuromuscular blockade, especially in the presence of significant patient-ventilator dyssynchrony, [75] but controlled trials have not convincingly demonstrated a mortality benefit. [76] The dangers of spontaneous ventilation on progression of lung injury must be weighed carefully alongside its beneficial effects in preventing respiratory muscle atrophy, and the risks with additional sedation and/or neuromuscular blockade to abrogate spontaneous efforts. [77] Pathophysiology of COVID-19 lung injury J o u r n a l P r e -p r o o f

The SARS-CoV-2 pandemic beginning in early 2020 has caused millions of deaths from severe COVID-19 lung injury and respiratory failure, often complicated by multisystem injury. While infection can present in myriad ways, SARS-CoV-2 is largely transmitted by aerosolization and typically causes symptoms of fatigue, malaise, fever, cough, sore throat, and dyspnea from pneumonitis, hypoxemia and respiratory failure. People of all ages and backgrounds are afflicted. Risk factors for poorer outcome include older age, obesity, male sex, diabetes, hypertension, cardiovascular disease, smoking, cancer, autoimmune disorders and other chronic diseases. Those with limited reserve, particularly in lung function, have the worst prognosis. While COVID-19 has been described as an atypical form of ARDS, the issue remains highly controversial, as pathophysiologic similarities with ARDS from other causes outnumber any differences (Table 1 ). In many ways, the advent of COVID-19 as a trigger for ARDS has reopened many questions on the pathophysiology of ARDS, itself.

The pathogenesis of COVID-19 lung injury involves direct viral damage and a host defense response with thrombotic and inflammatory reactions in the lung and elsewhere. [78] The alveolar epithelium and vascular endothelium express angiotensin-converting enzyme 2 (ACE-2) to which the virus attaches and then is internalized along with the membrane-bound ACE-2. Consequently, cellular damage ensues and evolves to interstitial edema and alveolar fluid filling, similar to the process of alveolar flooding in ARDS. Autopsy data, reflecting advanced disease, reveal typical ARDS features, including exudative proliferative and fibrotic phases of diffuse alveolar damage, hyaline membranes, alveolar and interstitial edema, atypical pneumocyte hyperplasia, alveolar hemorrhage, infarction, endothelial cell injury, and capillary congestion with microthrombosis and dilation. [79, 80] Notably, there is greater vasculopathy, including macro-and micro-thrombosis, endothelial cell injury, vascular dilation and aberrant angiogenesis [79, 81] in COVID-19 and the earlier SARS injury than with H1N1 influenza and ARDS. [82] However, lung biopsies in early COVID-19 [83] [84] [85] do not show the marked vascular pathology noted at autopsy. Limited bronchoalveolar lavage data demonstrate a more monocytic and lymphocytic predominance in the airspace typical of viral pneumonias [86] compared to the dominantly neutrophilic cell population in ARDS. [87] Understanding the respiratory pathophysiology of COVID-19 lung injury and ARDS is fundamental to better clinical care and support.

A possible unique ARDS presentation was reported by Gattinoni et al (2020) and followed up with a larger study of 32 patients [88] with potential implications for physiologic support. [89] In these studies a small fraction (< 20 %) had 'near normal' static total respiratory system compliance (C ST ) of 70-90 ml/cmH 2 O with an average of 50 ( Figure 7 ) compared with an average of 40 in series of ARDS patients. [90] On the basis of a slightly higher average C ST then observed in earlier ARDS patients, they proposed a controversial high compliance L phenotype (L for low elastance, low PEEP recruitability and more dominant low V A /Q gas exchange abnormality than shunt) combined with vasoplegia and loss of hypoxic pulmonary vasoconstriction (HPV). Nonetheless, many patients continue to worsen suggesting only a temporal sequence of early disease evolving to more classic ARDS pathophysiology. A small fraction of patients with a higher compliance of the L phenotype has been described in equal proportions in subsequent series. [91] [92] [93] [94] [95] This is neither unique to COVID-19 as shown in ARDS before the pandemic, [95] [96] [97] nor to patients with other influenza pneumonias requiring mechanical ventilation. [98] Several explanations for better compliance early in COVID-19 lung injury and even in ARDS are possible. The first is the predominantly peripheral and basilar ground glass opacities (GGO) very prevalent on CT imaging (Figure 8 ) early in the course of the disease. [99, 100] While never directly studied, GGOs by virtue of their lesser CT density than consolidations could be more compliant. This is suggested indirectly in patients, when dynamic (but not static) compliance was measured and surprisingly correlated with the volume of CT defined GGO, in contrast to a negative correlation with consolidated lung. [101] Surfactant producing AE type II cells express ACE-2 and contain almost 50 % of total lung surfactant. [102] With injury and release of these stores the compliance decline expected with microvascular leakage might be buffered, but only temporarily before surfactant inactivation occurs and production ceases. Hyaluronan, also produced by AE type II cells [103] as part of the alveolar glycocalyx, enhances surfactant function and reduces fluid accumulation; [104] in early injury before excessive accumulation occurs, it may limit surfactant inactivation. [105, 106] Several other aspects of compliance in ARDS and COVID-19 lung injury warrant discussion. The idea that a more vascular type injury may lead to better than expected compliance [101] runs counter to the fact that poorly perfused or non-perfused lung regions become stiffer, by hypocapnic pneumoconstriction and then by cessation of surfactant production. [107] This normal V A /Q matching mechanism based on responses to changes in local blood-borne CO 2 delivery redirects ventilation from poorly perfused regions to those with greater blood flow. Several studies have in fact found no correlation between the amount of affected lung by CT imaging and C ST . [108] [109] [110] It should also be pointed out that initial higher compliance is a poor predictor of risk and progression to severe lung injury in ARDS. [111] 

One proposed aspect of COVID-19 lung injury is vasoplegia and loss of HPV that may even result in paradoxical hyperperfusion. CT imaging of the vasculature shows large and small vessel dilations in areas of affected lung and dual energy CT perfusion imaging (Figure 9 ) reveals greater perfusion, particularly in GGO areas, supporting the possible idea of vasoplegia and dysregulated perfusion. [101, 112] Estimated PA pressures by transesophageal echocardiography in severe COVID-19 lung injury show only modestly elevations [113, 114] as in ARDS. [115, 116] This has now been corroborated with right heart catheterization data in 21 mechanically ventilated patients, showing mild pulmonary hypertension (mean PAP-27 mmHg, PVR-1.6 Woods units, and cardiac output-7.3 l/min). [117] These data do not rule out pulmonary hypertension (PH) in some with COVID-19 lung injury as there are case reports of right heart dysfunction and cor pulmonale consistent with either PH or myocardial viral J o u r n a l P r e -p r o o f injury. [118] At this time, all analyses of pulmonary hemodynamics are complicated by the likelihood of wide regional PVR differences such that vascular beds with low resistance and possible lack of HPV are counterbalanced by other areas of higher resistance due to obstruction from pulmonary embolism and/or in situ thrombosis, as observed in over 30 % of patients despite anticoagulant prophylaxis. [119] Loss of ACE-2 activity from internalization with the virus will result in less breakdown of vasoconstricting angiotensin II to its vasodilating and antiinflammatory metabolite Ang1-7. [120] In addition, bradykinin and some of its active edemapromoting metabolites are elevated in COVID-19, several of which are metabolized by ACE-2. [121] If HPV is blunted or absent, multiple mechanisms may be responsible. Reductions in alveolar PCO 2 will blunt HPV. [22] Another possibility is that SARS-CoV-2 may cause changes in proteins involved in vascular O 2 sensing. [122] Finally, viral-mediated alveolar-capillary endothelial cell injury [79, 81, 123, 124] may impair alveolar hypoxia sensing and transduction to the vascular smooth muscle. [125] Another explanation, unrelated to the above possible viral mediated effects, is that that those with hypoxemia out of proportion to the extent of lung involvement may have intrinsically blunted HPV at the low end of the wide 5-fold variation of this response among healthy persons. [22] It remains unknown whether HPV is altered in COVID-19 lung injury, since to do so would require brief testing with inspired hypoxic gas. As in ARDS, almitrine improves gas exchange in patients with COVID-19 lung injury, [126] as does inhaled nitric oxide. [127] However, since these drugs also alter PVR in normoxia, [128] [129] [130] they are not wholly ideal to evaluate HPV and thus do not clearly establish an alteration in HPV in patients with COVID-19 lung injury.

There have been alarming reports of what has been termed silent hypoxemia or happy hypoxia, denoting marked arterial hypoxemia despite an apparent lack of dyspnea in otherwise conscious and spontaneously breathing patients. Delirium associated with the infection may increase the presentation of silent hypoxemia. [131] The diagnosis of possible silent hypoxemia varies from a small minority of patients to as many as one third when assessed simply as the absence of dyspnea. [91, 92, [132] [133] [134] The hypoxemia can be profound, with values of SpO 2 and PaO 2 as low as 70 % and 40 mmHg, [135] yet surprisingly in the half century since the description of ARDS, silent hypoxemia has never been reported before. In reviews of ARDS, a few patients have presented without dyspnea, but no percentages are given and none in relation to the degree of severe hypoxemia. [87] In severe viral-induced ARDS, including SARS-CoV-1 and H1N1 influenza infection, those requiring oxygen without dyspnea ranged from 0 -27 % [111, [136] [137] [138] , suggesting this phenomenon is virally-mediated. In a recent analysis of pre-hospitalized patients, the average SpO 2 divided by respiratory rate was 5.0 in March 2020, compared to 3.2-3.5 in March of the preceding three years, suggestive of more silent hypoxemia and less tachypnea in the COVID-19 era. [139] Hypoxemia in COVID-19 as described in ARDS is caused by low ventilation to perfusion (V A /Q) mismatching and shunt. In ARDS there is no evidence for diffusion limitation, but this J o u r n a l P r e -p r o o f

has not yet been studied in COVID-19 lung injury using MIGET. Recently, detection of small bubbles with intravenous injection by transcranial Doppler correlated with hypoxemia and reduced compliance in patients with COVID-19 lung injury and was attributed to diffusion limitation due to microvascular dilations noted at autopsy. [140] However, normally occurring intrapulmonary arteriovenous anastomoses of similar diameters causing equal bubble scores in healthy people do not cause hypoxemia. [141] Modelling of early COVID-19 lung injury is conflicting. One study suggests the reported hypoxemia severity in early disease can be reasonably explained by a combination of pulmonary embolism, V A /Q mismatching in noninjured lung regions from redirection of blood flow from obstructed regions, and normal perfusion of the relatively small fraction of injured lung and does not require loss of HPV, hypoxic vasodilation or diffusion limitation. [142] Another finds that the L type phenotype can only be explained by hyperperfusion of collapsed lung regions, loss of HPV, extensive microvascular obstruction and diffusion limitation in affected areas. [143] Hypercapnia also develops in very severe COVID-19 lung injury for the same reasons as described earlier in the section on ARDS. As in ARDS, the entire spectrum of V A /Q mismatching contributes to the CO 2 dead space calculation. Reported values of dead space as high as 75% in COVID-19 lung injury [144] due largely to vascular obstruction, would be inconsistent with the mild pulmonary hypertension and preserved cardiac output in most patients noted above.

Absence of respiratory distress in some patients with COVID-19 lung injury include better-than-expected lung compliance (discussed above) with arterial hypocapnia in those that can increase ventilation sufficiently to partially blunt dyspnea arising from hypoxemia and other stimuli from the injured lung and elsewhere in the body. Furthermore, there is speculation that neural infection by SARS-CoV-2 (given the presence of ACE-2 in the carotid body [145] and elsewhere in the CNS [146] ) leads to a loss of normal perception of increased breathing from hypoxemia, lung irritant and stretch receptor activity, respiratory muscle effort, fever, anxiety, sympathetic nervous system activation, increased metabolism and metabolic acidosis. Other coronaviruses infect the brainstem via viral transmission along afferent nerves arising in the lung, nasopharynx and other peripheral mechano-and chemoreceptors. [147] Regarding the respiratory muscles, they express ACE-2 and can develop myopathic changes with infection that might lessen afferent signaling of their effort. [148] Control of ventilation and dyspnea perception are complex. [149] Afferent signals to the brain regarding breathing and its perception (Figure 10) include; a) chemoreception by peripheral and central chemoreceptors of arterial PO 2 , pH and PCO 2 , and b) signaling from the lungs, respiratory muscles and chest wall to the brainstem respiratory control center and its 'corollary projection' to higher cortical centers in the anterior insular cortex and amygdala, where the conscious sensation of breathing resides. [150] Signaling from peripheral and central chemoreceptors in response to arterial PCO 2 and PO 2 changes, like that of HPV, [22] varies 5 to 10-fold among individuals [151, 152] and is lower in older and diabetic patients. [135] In addition to interindividual variability of hypoxic ventilatory response (HVR), a similar high variability exists with the symptomatic dyspnea threshold onset during hypoxemia, with an observed threshold range of end-tidal PO 2 from 35-60 mmHg in healthy subjects maintained eucapnic at a fixed ventilation that likely correlates with HVR. [153] Whatever the pathophysiologic underpinnings of silent hypoxemia, it represents a significant threat for patients sent home with mild COVID-19 and told to seek care only when they become dyspneic or sicker. The fate of many with silent hypoxemia is one of eventual deterioration and death. It can be reasonably argued that many hours and days of severe unrecognized hypoxemia exacts a multi-organ toll, which if prevented sooner might improve outcomes since severe hypoxemia itself, in conjunction with systemic inflammation in COVID-19, contributes to further lung damage via exacerbation of local inflammatory injury. [154] Additionally, hypoxemia may contribute to hypercoagulability and thrombosis in the lung and other organs. [155] Hypoxia inducible factor-1 is increased in response to hypoxemia and in an animal model of herpes virus infection was shown to increase viral replication. [156] 

As already discussed, the numerous published large series of patients with COVID-19 lung injury and respiratory failure find little difference in many of the usual respiratory parameters of compliance, driving pressure, PEEP, V A /Q mismatching and shunt seen in ARDS. Accordingly, most physicians have employed low tidal volume ventilation with permissive hypercapnia, prone positioning, intermediate levels of PEEP, neuromuscular blockade, and conservative fluid therapy, in addition to pharmacologic therapies specific for COVID-19 as supportive data emerged. The concern raised for patients with the L type phenotype being harmed by smaller tidal volumes and higher PEEP has never been subjected to rigorous clinical trial and the improving survival rates of patients with severe COVID-19 to that with standard ARDS support suggests that harms of greater PEEP with overdistension and injury of more compliant lung (VILI) and hemodynamic compromise have not been realized.

Nonetheless, some aspects of COVID-19 have stimulated considerations of therapies either tried and found unsuccessful in ARDS or novel possibilities based up the pathophysiology of the injured lung in COVID-19. These include inhaled nitric oxide to improve V A /Q matching and reduce shunt by pulmonary vasodilation only in ventilated areas as well as possible direct viral killing and anti-inflammatory effects. Other forms of inhaled vasodilators including prostacyclin and its analogs are being used. Enhancement of HPV with almitrine in affected areas in the few countries where this is available has had success in improving oxygenation. The recent success with dexamethasone, as well as in ARDS [157] may be multifactorial beyond suppression of inflammation to include stimulation of fluid absorption, surfactant secretion and reduction in HPV. [158] Studies are underway to test whether the prominent hypercoagulopathy of COVID-19 may require higher dosing of standard prophylactic anticoagulants. The critical role of ACE-2 and its role in the setting the balance of the renin-angiotensin system offers the possibility of using Ang1-7 to reduce inflammation and reduce vasoconstriction. [159] Conclusions J o u r n a l P r e -p r o o f

The pathophysiology of ARDS and COVID-19 lung injury share many of the same aspects of reduced lung parenchymal compliance, vasculopathy, alveolar flooding and gas exchange impairment arising from direct infectious causes and non-infectious injuries. Exuberant host defense inflammatory responses lead to endothelial and epithelial cell damage and loss of the normally tight alveolar-capillary barrier and its ability to maintain a dry alveolar space for efficient gas exchange. The heterogenous regional extent of injury creates stress factors on surrounding lung that can further propagate injury with mechanical ventilation and possibly with vigorous spontaneous breathing efforts. While there may be some differences between ARDS and COVID-19 lung injury in aspects of lung compliance, pulmonary vascular responses and hypoxia sensing and responses, that may underlie the phenomenon of silent hypoxemia, these remain under considerable dispute as to whether they really are distinguishing and important enough to warrant different strategies of care. The pathophysiologic features of both lung injuries have important ramifications for life-sustaining supportive care and hopefully pharmacological therapies that may reduce mortality and enhance functional outcomes. Legend: The gas/tissue ratios reflecting the degree of uniformity of ventilated lung as a function of the distance between the sternum and the vertebrae. In the supine position, the gas/tissue ratio sharply decreases from the sternum to the vertebrae suggesting that both in normal and in patients with ARDS distending forces are about three times higher closer to the sternum than to the vertebrae. In prone position, the gas/tissue ratio is far more homogeneous, indicating a more even distribution of forces and more uniform ventilation throughout the lung. Legend: A stress raiser is a region of early injury that leads to inhomogeneous tissue forces that apply stress and strain to surrounding neighbor regions. An equal volume of gas is introduced into an area of normal lung (A) and into one with a stress raiser (either a collapsed or non-air filled region-the dark region in C). In a normal lung the introduced air with inflation is evenly distributed and leads to uniform inflation at minimal stress (B). In contrast, the lung with a stress raiser when further inflated (D) subjects the immediate neighboring regions (colored grey) to greater stress (and potential injury) as they are inflated, but the collapsed or fluid filled region itself is not inflated. Legend: Alveolar fluid clearance pathways in edematous uninjured lungs (A) and in ARDS (B). Both type I and II alveolar epithelial cells absorb sodium, chloride and water, respectively via epithelial sodium channels (ENaC), cystic fibrosis transmembrane conductance regulator (CFTR) and aquaporin-5 (AQ-5) channels. Energy dependent Na + /K + ATPase activity on the basolateral membrane of epithelial cells establishes an osmotic driving gradient for movement of sodium from the alveolar space into the interstitium for removal by capillary blood or lymphatic clearance. Chloride follows passively either by CFTR or paracellularly with water moving transcellularly via AQ-5 or paracellularly. Other cation channels not illustrated are also involved. These pathways along with surfactant maintain a dry and compliant alveolar space for efficient gas exchange. With injury to the lung (B) and loss of the normal tight alveolar capillary barrier such as in ARDS, fluid moves into the lungs and is less readily reabsorbed. Hypoxia and hypercapnia cause down-regulation and loss of the ion and water channels as well as Na + /K + ATPase activity. This may be compounded by various pro-inflammatory cytokines and mechanical ventilator induced lung injury involving high distending volumes and pressures. Legend: Schematic representation of the multiple afferent signaling pathways to the brainstem respiratory centers that control ventilation from mechano-stretch receptors in muscles and joints, irritant and stretch receptor in the lungs, arterial PO 2 and PCO 2 (from peripheral chemoreceptors in the carotid body, arterial pH and PCO 2 (from central chemoreceptors in the brainstem), fear, emotional and pain stimuli from the hypothalamus. Signals from the brainstem are also conveyed (corollary projection) to the conscious regions of the brain (amygdala and insular cortex) that perceive dyspnea, work of breathing and respiratory distress. In COVID-19 it is proposed that some of this signaling and cortical perception may be impaired by direct viral injury to these pathways. 

Current incidence and outcome of the acute respiratory distress syndrome

Macrophage receptors and immune recognition

Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin

Salt and water transport across alveolar and distal airway epithelia in the adult lung

Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome

The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome

Ventilation-perfusion distributions in the adult respiratory distress syndrome

Velocity of CO2 exchange in blood

What do dead-space measurements tell us about the lung with acute respiratory distress syndrome? Respiratory Care

Causes of a high physiological dead space in critically ill patients

Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome

Pulmonary Dead Space Monitoring: Identifying Subjects With ARDS at Risk of Developing Right Ventricular Dysfunction

Fifty years of research in ARDS. Gas exchange in acute respiratory distress syndrome

Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome

Effects of inspired carbon dioxide on ventilationperfusion matching in normoxia, hypoxia, and hyperoxia

High CO 2 levels impair alveolar epithelial function independently of pH

A Comprehensive Review of Prone Position in ARDS

Prostacyclin for the Treatment of Pulmonary Hypertension in the Adult Respiratory Distress Syndrome: Effects on Pulmonary Capillary Pressure and Ventilation-Perfusion Distributions

Probing the regional distribution of pulmonary gas exchange through single-breath gas-and dissolved-phase 129Xe MR imaging

Prone position in ARDS patients: why, when, how and for whom

Gravity is an important but secondary determinant of regional pulmonary blood flow in upright primates

Hypoxic pulmonary vasoconstriction

Hypoxic pulmonary vasoconstriction in nonventilated lung areas contributes to differences in hemodynamic and gas exchange responses to inhalation of nitric oxide

Inhaled nitric oxide, almitrine infusion, or their coadministration as a treatment of severe hypoxemic focal lung lesions

Stress distribution in lungs: a model of pulmonary elasticity

The concept of "baby lung

Fifty years of research in ARDS. Respiratory mechanics in acute respiratory distress syndrome

Measurements of functional residual capacity during intensive care treatment: the technical aspects and its possible clinical applications

Bedside estimation of nonaerated lung tissue using blood gas analysis

Preservation of normal lung regions in the adult respiratory distress syndrome: analysis by computed tomography

Vertical gradient of regional lung inflation in adult respiratory distress syndrome

Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity

Esophageal manometry and regional transpulmonary pressure in lung injury

Respiratory restriction and elevated pleural and esophageal pressures in morbid obesity

Lung inhomogeneities and time course of ventilator-induced mechanical injuries

The POOR Get POORer: A Hypothesis for the Pathogenesis of Ventilator-Induced Lung Injury

Lung repair and regeneration in ARDS: role of PECAM1 and Wnt signaling

Pressure-volume curve of total respiratory system in acute respiratory failure: computed tomographic scan study

Lung inhomogeneities, inflation and [18F] 2-fluoro-2-deoxy-Dglucose uptake rate in acute respiratory distress syndrome

Lungs of patients with acute respiratory distress syndrome show diffuse inflammation in normally aerated regions: a [18F]-fluoro-2-deoxy-D-glucose PET/CT study

Analysis of behavior of the respiratory system in ARDS patients: effects of flow, volume, and time

Lung emptying in patients with acute respiratory distress syndrome: effects of positive end-expiratory pressure

Pathogenesis of Acute Respiratory Distress Syndrome. Semin Respir Crit Care Med

Novel role for CFTR in fluid absorption from the distal airspaces of the lung

Structure and function of aquaporin water channels

Stimulation of alveolar epithelial fluid clearance in human lungs by exogenous epinephrine

Effects of vasoconstrictive and vasodilative agents on lymphatic smooth muscles in isolated canine thoracic ducts

Effect of intravenous β-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. The Lancet

Randomized, placebo-controlled clinical trial of an aerosolized β2-agonist for treatment of acute lung injury

Increased surface tension favors pulmonary edema formation in anesthetized dogs' lungs

Impact of mechanical ventilation on the pathophysiology of progressive acute lung injury

Ventilator-induced lung injury

Biotrauma and Ventilator-Induced Lung Injury: Clinical Implications

Ventilator-related causes of lung injury: the mechanical power

Experimental pulmonary edema due to intermittent positive pressure ventilation with high inflation pressures. Protection by positive end-expiratory pressure

Nitrogen washout/washin, helium dilution and computed tomography in the assessment of end expiratory lung volume

ECMO criteria for influenza A (H1N1)-associated ARDS: role of transpulmonary pressure

Tidal hyperinflation during low tidal volume ventilation in acute respiratory distress syndrome

Electrical impedance tomography in acute respiratory distress syndrome

Tidal ventilation at low airway pressures can augment lung injury

Histologic aspects of pulmonary barotrauma in critically ill patients with acute respiratory failure

Airway closure in acute respiratory distress syndrome: an underestimated and misinterpreted phenomenon

Ventilator-induced lung injury: lessons from experimental studies

Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial

Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distress syndrome: a randomized controlled trial

Open lung approach for the acute respiratory distress syndrome: a pilot, randomized controlled trial

An open lung strategy in the management of acute respiratory distress syndrome: a systematic review and metaanalysis

Mechanical ventilation guided by esophageal pressure in acute lung injury

Implementing a bedside assessment of respiratory mechanics in patients with acute respiratory distress syndrome

Biotrauma and ventilator-induced lung injury: clinical implications

Spontaneous breathing during lung-protective ventilation in an experimental acute lung injury model: high transpulmonary pressure associated with strong spontaneous breathing effort may worsen lung injury

Acute respiratory failure following pharmacologically induced hyperventilation: an experimental animal study

Exacerbation of acute pulmonary edema during assisted mechanical ventilation using a low-tidal volume, lung-protective ventilator strategy

Effects of positive end-expiratory pressure and spontaneous breathing activity on regional lung inflammation in experimental acute respiratory distress syndrome

Fifty years of research in ARDS. Spontaneous breathing during mechanical ventilation. Risks, mechanisms, and management

Early neuromuscular blockade in the acute respiratory distress syndrome

Long-term effects of spontaneous breathing during ventilatory support in patients with acute lung injury

Tissue-specific Immunopathology in Fatal COVID-19

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study. The Lancet Infectious Diseases

The pulmonary vascular lesions of the adult respiratory distress syndrome

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Lung Histopathology in Coronavirus Disease 2019 as Compared With Severe Acute Respiratory Sydrome and H1N1 Influenza: A Systematic Review

Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer

Radiology-pathology Correlation in Recovered COVID-19, Demonstrating Organizing Pneumonia

Early histologic findings of pulmonary SARS-CoV-2 infection detected in a surgical specimen

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Acute respiratory distress syndrome

Physiological and quantitative CT-scan characterization of COVID-19 and typical ARDS: a matched cohort study

Management of COVID-19 respiratory distress

Is severe COVID-19 pneumonia a typical or atypical form of ARDS? And does it matter?

Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study

Covid-19 in critically ill patients in the Seattle regioncase series

Lung Recruitability in COVID-19-associated Acute Respiratory Distress Syndrome: A Single-Center Observational Study

Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study. The lancet Respiratory medicine

Respiratory physiology of COVID-19-induced respiratory failure compared to ARDS of other etiologies

Prone positioning in severe acute respiratory distress syndrome

Compliance Phenotypes in Early ARDS Before the COVID-19 Pandemic

Comparison of Clinical Features and Outcomes in Critically Ill Patients Hospitalized with COVID-19 versus Influenza

Chest CT in the Emergency Department for Diagnosis of COVID-19 Pneumonia: Dutch Experience

Chest x-ray findings and temporal lung changes in patients with COVID-19 pneumonia

Pulmonary Angiopathy in Severe COVID-19: Physiologic, Imaging and Hematologic Observations

Biology of surfactant

Isolation and characterization of glycosaminoglycans secreted by human foetal lung type II pneumocytes in culture

On Top of the Alveolar Epithelium: Surfactant and the Glycocalyx

Presence of hyaluronan in lung alveoli in severe Covid-19: An opening for new treatment options?

Hyaluronan with dextran added to therapeutic lung surfactants improves effectiveness in vitro and in vivo

The Unappreciated Role of Carbon Dioxide in Ventilation/Perfusion Matching

Subphenotyping ARDS in COVID-19 Patients: Consequences for Ventilator Management

Respiratory Mechanics of COVID-19 vs. Non-COVID-19 Associated Acute Respiratory Distress Syndrome

Recruitability and effect of PEEP in SARS-Cov-2-associated acute respiratory distress syndrome

Clinical manifestations and inflammatory cytokine responses in patients respiratory syndrome

Pulmonary vascular manifestations of COVID-19 pneumonia

Cardiovascular phenotypes in ventilated patients with COVID-19 acute respiratory distress syndrome

Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19

Hemodynamic profile in severe ARDS: results of the European Collaborative ARDS Study

National Institutes of Health/National Heart, Lung, and Blood Institute ARDS Network. Pulmonary vascular dysfunction is associated with poor outcomes in patients with acute lung injury

Haemodynamic characteristics of COVID-19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Reninangiotensin-aldosterone system inhibitors in patients with Covid-19

Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection

Differentiating COVID-19 Pneumonia from Acute Respiratory Distress Syndrome (ARDS) and High Altitude Pulmonary Edema (HAPE): Therapeutic Implications

Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

The endothelium in hypoxic pulmonary vasoconstriction

Treating hypoxemic COVID-19" ARDS" patients with almitrine: The earlier the better? Anaesthesia

Inhaled nitric oxide treatment in spontaneously breathing COVID-19 patients. Therapeutic Advances in Respiratory Disease

Enhancement of hypoxic pulmonary vasoconstriction by low dose almitrine bismesylate in normal humans

The effect of amlodipine on respiratory and pulmonary vascular responses to hypoxia in mountaineers

Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study

Delirium in Older Patients With COVID-19 Presenting to the Emergency Department

Clinical and immunological features of severe and moderate coronavirus disease 2019

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study. The Lancet Respiratory Medicine

Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis

Why COVID-19 silent hypoxemia is baffling to physicians

A retrospective study of 78 patients with severe acute respiratory syndrome

Clinical features and outcomes of severe acute respiratory syndrome and predictive factors for acute respiratory distress syndrome

Severe refractory hypoxaemia in H1N1 (2009) intensive care patients: initial experience in an Asian regional hospital

Prehospital pulse oximetry: a red flag for early detection of silent hypoxemia in COVID-19 patients

Pulmonary vascular dilatation detected by automated transcranial doppler in COVID-19 pneumonia

Positive Bubble Study in Severe COVID-19: Bubbles May be Unrelated to Gas Exchange Impairment

Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia

Silico Modeling of Coronavirus Disease 2019 Acute Respiratory Distress Syndrome: Pathophysiologic Insights and Potential Management Implications

Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study

The role of local renin-angiotensin system in arterial chemoreceptors in sleepbreathing disorders

Does COVID19 infect the brain? If so, smokers might be at a higher risk

The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients

Investigators DC-D. Diaphragm Pathology in Critically Ill Patients With COVID-19 and Postmortem Findings From 3 Medical Centers

statement: update on the mechanisms, assessment, and management of dyspnea

COVID-19 respiratory distress: not so much 'happy hypoxia' as 'silent hypoxemia

Diuretic effect of acute hypoxia in humans: relationship to hypoxic ventilatory responsiveness and renal hormones

The relationship of hypercapnic ventilatory responses to age, gender and athleticism

Hypoxic and hypercapnic drives to breathe generate equivalent levels of air hunger in humans

Hypoxia and inflammation

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China

A role of hypoxiainducible factor 1 alpha in Mouse Gammaherpesvirus 68 (MHV68) lytic replication and reactivation from latency

Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial

Clinical practice: Acute high-altitude illnesses

Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges